INSIGHTS ON CELL & GENE THERAPY DISCOVERY

• CRISPR Nucleases And Proprietary Reverse Transcriptases For Precise Gene Editing

  Mining a database of over 10 billion natural proteins has yielded proprietary reverse transcriptases and engineered RT editing systems capable of achieving precise gene editing in vivo.

• Improving Speed, Reproducibility And Flexibility In Cellular Imaging

  See how automated microscopy combines imaging, robotics, and software to reduce manual intervention and support complex cellular imaging workflows configured around specific applications.

• Enabling Process Monitoring, Product Characterization, And Quality Control

  Optical microscopy reveals biological structures, behaviors, and interactions throughout development. Learn how advanced imaging and analysis support cellular research and more.

• Why The Traditional Approach To Evaluating Gene Editing Is Not Your Only Option

  De-risk genetic medicine development with a phased evaluation approach. Gain rapid, data-driven feasibility insights before major investments, enabling smarter decisions and faster clinical progress.

• Robust Database Characterizes And Optimizes Product Development

  Integrating material characterization data with process parameters accelerates drug development, reduces empirical testing, and strengthens regulatory compliance.

• CRISPR-Cas9 KO Cell Line Generation And Development

  See how CRISPR-generated FKRP knockout muscle cells and a high-throughput On-Cell Western method can quantify α-dystroglycan glycosylation restoration and support rAAV-FKRP potency testing.

• Receptor Occupancy In The Era Of Multispecific Therapeutics

  Receptor occupancy studies face new challenges as multispecific therapeutics introduce complex target engagement, receptor trafficking, cellular interactions, and assay interpretation considerations.

• Patient-Derived Organoids For Cell Therapy Development

  Patient-derived organoids offer a more accurate way to test cell therapies by preserving the complex tumor environments that determine whether these treatments will actually work.

• Moving Beyond Animal Models With iPSC-Based Models

  Animal models are giving way to iPSC-based systems that better reflect human biology, offering researchers a more accurate and ethical path to drug discovery.

• Modeling Neurodegenerative Disorders: Where Are We Now?

  Neurodegenerative disease research faces a critical gap between symptom management and disease modification, making better preclinical models an urgent priority for the field.